OBJECTIVE: This review aimed to determine the efficacy of blue-wavelength light therapy (BWLT) for post-traumatic brain injury (TBI) sleepiness, sleep disturbance, depression, and fatigue. METHODS: Pubmed, Scopus, Web of Science, Cochrane Library, Academic Search Complete, and CINAHL. Included trials were randomized controlled trials (RCTs) of BWLT in adults with a history of TBI. Outcomes of interest included sleepiness, sleep disturbance, depression, or fatigue. Two reviewers independently screened the searched items, selected the trials, extracted the data, and rating the quality of trials. We aggregated the data using a random-effect, frequentist network meta-analysis (NMA). RESULTS: We searched the databases on July 4, 2020. This review included four RCTs of 117 patients with a history of TBI who were randomized to received BWLT, amber light therapy (ALT), or no light therapy (NLT). Moderate-quality evidence revealed that: i) BWLT was significantly superior to NLT in reducing depression (SMD = 0.81, 95% CI = 0.20 to 1.43) ii) BWLT reduced fatigue at a significantly greater extent than NLT (SMD = 1.09, 95% CI = 0.41 to 1.76) and ALT (SMD = 1.00, 95% CI = 0.14 to 1.86). Low-quality evidence suggested that BWLT reduced depression at a greater extent than ALT (SMD = 0.57, 95% CI = 0.04 to 1.10). Low-quality evidence found that the dropout rates of those receiving BWLT and ALT were not significantly different (RR = 3.72, 95% CI = 0.65 to 21.34). CONCLUSION: Moderate-quality evidence suggests that BWLT may be useful for post-TBI depression and fatigue.
OBJECTIVE: This review aimed to determine the efficacy of blue-wavelength light therapy (BWLT) for post-traumatic brain injury (TBI) sleepiness, sleep disturbance, depression, and fatigue. METHODS: Pubmed, Scopus, Web of Science, Cochrane Library, Academic Search Complete, and CINAHL. Included trials were randomized controlled trials (RCTs) of BWLT in adults with a history of TBI. Outcomes of interest included sleepiness, sleep disturbance, depression, or fatigue. Two reviewers independently screened the searched items, selected the trials, extracted the data, and rating the quality of trials. We aggregated the data using a random-effect, frequentist network meta-analysis (NMA). RESULTS: We searched the databases on July 4, 2020. This review included four RCTs of 117 patients with a history of TBI who were randomized to received BWLT, amber light therapy (ALT), or no light therapy (NLT). Moderate-quality evidence revealed that: i) BWLT was significantly superior to NLT in reducing depression (SMD = 0.81, 95% CI = 0.20 to 1.43) ii) BWLT reduced fatigue at a significantly greater extent than NLT (SMD = 1.09, 95% CI = 0.41 to 1.76) and ALT (SMD = 1.00, 95% CI = 0.14 to 1.86). Low-quality evidence suggested that BWLT reduced depression at a greater extent than ALT (SMD = 0.57, 95% CI = 0.04 to 1.10). Low-quality evidence found that the dropout rates of those receiving BWLT and ALT were not significantly different (RR = 3.72, 95% CI = 0.65 to 21.34). CONCLUSION: Moderate-quality evidence suggests that BWLT may be useful for post-TBI depression and fatigue.
Authors: Joshua B Cantor; Teresa Ashman; Wayne Gordon; Annika Ginsberg; Clara Engmann; Matthew Egan; Lisa Spielman; Marcel Dijkers; Steve Flanagan Journal: J Head Trauma Rehabil Date: 2008 Jan-Feb Impact factor: 2.710
Authors: Annette van Maanen; Anne Marie Meijer; Kristiaan B van der Heijden; Frans J Oort Journal: Sleep Med Rev Date: 2015-09-09 Impact factor: 11.609
Authors: Sarah Laxhmi Chellappa; Roland Steiner; Peter Blattner; Peter Oelhafen; Thomas Götz; Christian Cajochen Journal: PLoS One Date: 2011-01-26 Impact factor: 3.240
Authors: Laura J Connolly; Shantha M W Rajaratnam; Jade M Murray; Gershon Spitz; Steven W Lockley; Jennie L Ponsford Journal: BMC Neurol Date: 2021-07-05 Impact factor: 2.474